Skip to content

Efficacy and safety of ivermectin against Trichuris trichiura

Efficacy and safety of ascending dosages of ivermectin against Trichuris trichiura in preschool- and school-aged children: a randomized controlled trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN15871729
Enrollment
290
Registered
2017-05-19
Start date
2017-05-25
Completion date
Unknown
Last updated
2019-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Trichuris infection Infections and Infestations Trichuris infection

Interventions

Sponsors

Swiss Tropical and Public Health Institute
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Written informed consent signed by either participating PK patient or for the study involving children parents and/or caregiver; and oral assent by child (aged 6-12 years) 2. Able and willing to be examined by a study physician at the beginning of the study 3. Able and willing to provide two stool samples at the beginning (baseline) and approximately three weeks after treatment (follow-up) 4. Corresponding age to be included in the respective age groups of interest (i.e. between 2 to 5 years for preschoolers, between 6 to 12 for school-aged children or =21 years for the adult age group sample) 5. Positive for T. trichiura eggs in the stool 6. Absence of major systemic illnesses, e.g. severe anemia, clinical malaria as assessed by a medical doctor, upon initial clinical assessment 7. No known or reported history of chronic illness as cancer, diabetes, chronic heart, liver or renal disease 8. No recent anthelminthic treatment (within past 4 weeks) 9. No known allergy to study medications (i.e., ivermectin)

Exclusion criteria

Exclusion criteria: 1. No written informed consent by individual/parents and/or caregiver 2. Presence of major systemic illnesses, e.g. severe anemia, clinical malaria as assessed by a medical doctor, upon initial clinical assessment 3. History of acute or severe chronic disease 4. Recent use of anthelminthic drug (within past 4 weeks) 5. Attending other clinical trials during the study 6. Negative diagnostic result for T. trichiura eggs in the stool

Design outcomes

Primary

MeasureTime frame
Cure rate (CR) (conversion from being egg positive pre-treatment to egg negative post-treatment) for Trichuris infection will be assessed using the quadruple Kato-Katz method at 21 days post-treatment.

Secondary

MeasureTime frame
1. Egg reduction rate for Trichuris infection will be assessed using the quadruple Kato-Katz method at 21 days post-treatment 2. Cure rate and egg reduction rate for concomitant soil-transmitted helminth infections will be assessed using the quadruple Kato-Katz method at 21 days post-treatment 3. Safety will be assessed with evaluation of adverse events of the treated subjects based on interviews at 3, 24, and 72 hours after treatment 4. Pharmacokinetic parameters: drug concentrations will be measured with a validated LC/MS method at baseline, 2, 4, 6, 7, 8, 9, 24, 48 and 72 hours post treatment

Countries

Cote d'Ivoire

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 3, 2026